云顶新耀医药科技有限公司 Mediaroom

Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

* Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with...

2026-04-08 10:21 8381

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China

SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-23 10:24 4122

Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited

SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-18 11:07 8922

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call

SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-16 17:58 5857

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

* VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, ...

2026-03-13 18:05 5897

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2026-03-10 18:40 4728

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China

SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2026-03-09 21:27 7877

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2026-02-06 13:10 7151

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2026-02-05 08:17 5937

Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2026-01-06 07:58 11513

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-12-17 16:10 3679

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-12-15 12:40 3685

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

- Accretive Commercialization Services Agreement covering six mature assets across critical care, c...

2025-12-11 23:57 3934

Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

* The first patient had received the first dose of EVM14 injection in a global, multi-center Phas...

2025-11-21 12:01 2869

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-...

2025-10-30 11:05 2081

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-10-14 12:13 1709

Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receiv...

2025-10-13 08:47 1743

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized...

2025-10-09 13:10 1725

Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium

* 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Ne...

2025-09-15 07:45 5359

Everest Medicines Announces Interim Results for First Half of 2025

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-08-29 07:52 3852

Latest News